Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium-177 dotatate + capecitabine
- Development stage
- Unknown
- Lead developer
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
lutetium-177 dotatate + capecitabine is a combination therapy regimen being investigated for the treatment of aggressive, FDG-positive gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). The regimen consists of Peptide Receptor Radionuclide Therapy (PRRT) using lutetium-177 dotatate, which delivers targeted beta-radiation to cells expressing somatostatin receptor type 2 (SSTR2), combined with low-dose metronomic capecitabine. Capecitabine, an oral fluoropyrimidine carbamate, acts as a radiosensitizer and anti-angiogenic agent, potentially enhancing the efficacy of the radionuclide therapy. This specific combination is being evaluated in clinical trials led by the Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori IRCCS.
- Brand names
- LutatheraXeloda
- Other names
- Lu-PRRT + capecitabine177Lu-DOTATATE + capecitabineLu-PRRT Plus Capecitabine
02
Targets
TS (Thymidylate synthase)SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on lutetium-177 dotatate + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium-177 dotatate + capecitabine.